ClinicalTrials.gg
RecruitingNCT05946824DASBRT-RPCUpdated Oct 8, 2024

This Study is Evaluating a New Radiation Treatment Technique for Patients Who Have Had Prostate Cancer, Undergone Surgery for Cancer, and Then Have Evidence That Their Prostate Cancer Has Returned.

A Phase 2 interventional study of Daily-adaptive Stereotactic Body Radiation Therapy and Daily-adaptive Stereotactic Body Radiation Therapy in Recurrent Prostate Cancer After Surgery, sponsored by University of Rochester. Recruiting at 1 site in United States. Open to male participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-08.

Sponsored by University of Rochester · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Dec 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Non-randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Prostatic Neoplasms by University of Rochester — 4 open to participants now, 4 under way, 1 of them phase 3. Prostatic Neoplasms · University of Rochester.

Planned enrollment
6th of 12
80 · median 76
Started
2023
with 1 other
Phase 2
3 of 12
1 open now
Registered
11th of 12
by date

Among the 12 studies in Prostatic Neoplasms by University of Rochester, this one is the 6th largest by planned enrollment, is one of 2 that started in 2023, is one of 3 in phase 2, and was the 11th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

4 of the 12 studies in Prostatic Neoplasms by University of Rochester are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Prostatic Neoplasms by University of Rochester, or all of them as a file.
02

Study summary

There is significant, proven use of radiation for recurrent prostate cancer after surgical resection. This treatment typically is delivered over seven and a half weeks of daily treatments, presenting a burden to patients and the health care system. Stereotactic body radiation (SBRT) is a radiation technique in which large doses are delivered over a short period of time. To date there is extremely limited evidence in SBRT for recurrent prostate cancer after surgery, with a significantly growing body of evidence for primary SBRT treatment of prostate cancer in men who opt for non-surgical upfront treatment. Additionally, advances in imaging have allowed better detection of the site of recurrence, and novel artificial intelligence aided daily-adaptive radiation therapy have allowed more precise delivery of radiation doses. This study seeks to evaluate the role of Daily-Adaptive with AI-assisted SBRT in the post operative setting utilizing Ethos Plan Adaptive technology in attempt to maintain control and minimize side effects.

Read the detailed description

This will be a two cohort Phase II single center, prospective trial, with a safety lead-in component. This design will allow an initial toxicity assessment phase of a novel radiation treatment schema that is based on other literature, but with limited evidence. There is no plan to escalate the dose. Pending assessment of the safety lead in, complete enrollment will be permitted. Each cohort will be analyzed separated for the safety lead in. There will be 7 patients in the safety lead in cohorts. The stopping point will be an incidence of 2 cases of CTCAE v5.0 Grade 3+ acute toxicity attributed to therapy within gastrointestinal or urinary domains. This generally entails symptoms significant enough to require a procedure or limit basic levels of daily activity (bathing, cooking). Actue toxicity of a comparable magnitude has been reported in the 1-5% rate in a recent meta-analysis of contemporary trials which utilized standard of care radiation. Thus two cases would represent an unacceptable increased toxicity level, and a cohort size of 7 is approximate the commonly accepted size in Phase I escalation studies to evaluate dose limiting toxicity.

03

Conditions studied

  • Recurrent Prostate Cancer After Surgery

Browse trials for

Keywords

  • Stereotactic body radiation therapy
  • daily-adaptive radiation therapy
  • prostate cancer
  • recurrent prostate cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adenocarcinoma of the prostate with previous surgical resection
  • Radiologically detected prostate bed OR regional nodal recurrence defined as iliac, obturator, perirectal or pre-sacral node generally encompassing below the aortic bifurcation
  • Prostate bed recurrence as occurring within the region of the prostate or RTOG consensus definition of the surgical field
  • At least two serum detectable PSA levels defined as >0.02 ng/dl at least 30 days apart.

Exclusion criteria

Exclusion Criteria:

  • disease
  • Prior radiation therapy to the pelvis region
  • Inflammatory bowel disease
  • Hospitalization for a gastrointestinal diagnosis in the preceeding 3 months
  • Hospitalization for a urinary tract issue / diagnosis in the preceeding 3 months
  • PSA >10 ng/dl at study entry,
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    1 - Prostate bed only recurrence

    Patients with confirmed radiologic recurrence of their prostate cancer in the defined region of the previous prostate surgery - commonly referred to as the prostate surgical bed.

    Radiation: Daily-adaptive Stereotactic Body Radiation Therapy

  • Experimental
    2- Pelvic nodal with or without a prostate bed recurrence

    Patients who have a radiologic recurrence of prostate cancer in the pelvic node region

    Radiation: Daily-adaptive Stereotactic Body Radiation Therapy

Interventions

  • RadiationDaily-adaptive Stereotactic Body Radiation Therapy

    Daily-adaptive radiation therapy to two dose levels - one to the area of radiologic recurrent nodal disease, and a lower, prophylactic dose to the standard post-prostatectomy and larger pelvic node fields

  • RadiationDaily-adaptive Stereotactic Body Radiation Therapy

    Daily-adaptive radiation therapy to two areas - a high dose to the area of radiologic recurrence, and a lower, prophylactic dose to the standard post-prostatectomy fields

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability])

    The Primary objective of the safety lead in component is to report acute, attributable genitourinary and gastrointestinal toxicity as scored by CTCAE v5.0.

    Time frame: 1-2 years

  2. The primary objective of the full enrollment Phase II component is to report biochemical recurrence free survival (bPFS).

    We will utilize a globally standard definition of bPFS which was defined in the RADICALS(6) international trial as follows: freedom from PSA of 0·4 ng/mL or greater following postoperative radiotherapy, or PSA of more than 2·0 ng/mL at any time following therapy, clinical progression, or initiation of non-protocol hormone therapy, or death from any cause.

    Time frame: 5 years

Secondary outcomes

  1. Long term side effects

    Late patient toxicity as defined by EPIC-IPSS prostate QoL forms

    Time frame: 5 years

  2. Distant metastasis free survival

    Development of metastatic prostate cancer to other parts of the body

    Time frame: 5 years

  3. Need for long term anti-testosterone therapy

    Time to initiation of non-protocol hormonal therapy, if needed

    Time frame: 5 years

Other outcomes

  1. Planning parameters and techniques

    Identification of novel artificial-intelligence aided planning techniques, algorithms, and utilization as uncovered during the course of therapy

    Time frame: 5 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Nov 2025, 23 months after the start.

Of 613 non-industry phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 86. This study's planned 23 months is below that.

Counting every sponsor, half of 727 studies reached it within 53 months; a quarter within 34 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2023
First posted
Jul 14, 2023
StartActual
Dec 14, 2023
Primary completionEst.
Nov 24, 2025
CompletionEst.
Nov 24, 2028
Last update
Oct 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05946824
Responsible party
Michael Cummings (Michael Andrew Cummings, M.D., Assistant Professor of Radiation Oncology, University of Rochester) — Principal investigator
First posted
Jul 14, 2023
Start date
Dec 14, 2023
Primary completion
Nov 24, 2025 (estimated)
Completion
Nov 24, 2028 (estimated)
Last update
Oct 8, 2024

Study contacts

Michael Cummings, MD
Contact
michael_cummings@urmc.rochester.edu
585-275-5622

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion